To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

ClinicalTrials.gov ID: NCT03330847

Public ClinicalTrials.gov record NCT03330847. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).

Study identification

NCT ID: NCT03330847
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 273 participants

Conditions and interventions

Conditions

Metastatic Triple Negative Breast Cancer

Interventions

Olaparib Continuous (28-Day cycle) 300 mg BD. Drug
Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle). Drug
Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle). Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 130 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 6, 2018
Primary completion: Nov 12, 2020
Completion: Oct 8, 2026
Last update posted: Jul 1, 2026

2018 – 2026

United States locations

U.S. sites: 20
U.S. states: 15
U.S. cities: 20

Facility	City	State	ZIP	Site status
Research Site	Birmingham	Alabama	35205	—
Research Site	Anchorage	Alaska	99508	—
Research Site	Gilbert	Arizona	85234	—
Research Site	Aurora	Colorado	80045	—
Research Site	New Haven	Connecticut	06511	—
Research Site	Chicago	Illinois	60637	—
Research Site	Munster	Indiana	46321	—
Research Site	Hazard	Kentucky	41701	—
Research Site	Louisville	Kentucky	40207	—
Research Site	Towson	Maryland	21204	—
Research Site	Brick	New Jersey	08724	—
Research Site	East Setauket	New York	11733	—
Research Site	Lake Success	New York	11042	—
Research Site	Mineola	New York	11501	—
Research Site	Mount Kisco	New York	10549	—
Research Site	Stony Brook	New York	11794	—
Research Site	Cincinnati	Ohio	45219	—
Research Site	Knoxville	Tennessee	37909	—
Research Site	Seattle	Washington	98104	—
Research Site	Milwaukee	Wisconsin	53212	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 121 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03330847, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 1, 2026 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03330847 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →